|
Benitec Biopharma Ltd is an Australian biotechnology company founded in 1997.〔(【引用サイトリンク】title=Australian Securities Exchange )〕 It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.〔(【引用サイトリンク】title= GlobalData Financial and Strategic SWOT Analysis Review )〕 RNA interference (RNAi) was awarded the Nobel Prize in Physiology or Medicine in 2006. The Commonwealth Scientific and Industrial Research Organisation (CSIRO) has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.〔(【引用サイトリンク】title= Licensing RNAi gene technology. CSIRO. 14 Oct 2011 )〕 == Partnerships and Collaborations == Benitec Biopharma and its subsidiary Tacere Therapeutics has partnerships with:〔〔〔(【引用サイトリンク】title= Australian Life Scientist. CSIRO, Benitec strengthen RNAi patent positions. 24 October 2005 )〕 * For laboratory reagents: Promega, Chemicon (Millipore Corporation), Integrated DNA Technologies, Genscript, Ambion Inc (Applied Biosystems), Origene Technologies Inc, Sigma Aldrich * For transgenic animals: Artemis Pharmaceutical GmbH, GenOway * For commercial research use: Merck & Co, Pfizer * Licensing agreements: Calimmune (US), Carnegie Institution for Science (University of Massachusetts, US), Children’s Cancer Institute Australia for Medical Research (CCIA) (University of New South Wales, Australia), Biomics Biotechnologies (China), Genable Technologies (Ireland), Stanford University (US), Royal Holloway (University of London, UK), Revivicor (US), Regen BioPharma (a subsidiary of Bio-Matrix, US), and UniQure BV (the Netherlands). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Benitec Biopharma Ltd」の詳細全文を読む スポンサード リンク
|